Infection and Drug Resistance Dovepress Patterns of Resistance Development with Integrase Inhibitors in Hiv

Raltegravir, the only integrase (IN) inhibitor approved for use in HIV therapy, has recently been licensed. Raltegravir inhibits HIV-1 replication by blocking the IN strand transfer reaction. More than 30 mutations have been associated with resistance to raltegravir and other IN strand transfer inhibitors (INSTIs). The majority of the mutations are located in the vicinity of the IN active site within the catalytic core domain which is also the binding pocket for INSTIs. High-level resistance to INSTIs primarily involves three independent mutations at residues Q148, N155, and Y143. The mutations significantly affect replication capacity of the virus and are often accompanied by other mutations that either improve replication fitness and/or increase resistance to the inhibitors. The pattern of development of INSTI resistance mutations has been extensively studied in vitro and in vivo. This has been augmented by cell-based phenotypic studies and investigation of the mechanisms of resistance using biochemical assays. The recent elucidation of the structure of the prototype foamy virus IN, which is closely related to HIV-1, in complex with INSTIs has greatly enhanced our understanding of the evolution and mechanisms of IN drug resistance.

[1]  D. Hazuda,et al.  Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[2]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[3]  R. Kaiser,et al.  Evolution of raltegravir resistance during therapy. , 2009, The Journal of antimicrobial chemotherapy.

[4]  Marie-Pierre de Béthune,et al.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.

[5]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[6]  F. Vaida,et al.  Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1 , 2010, Antimicrobial Agents and Chemotherapy.

[7]  L. Whitaker.  Treatment and Prevention , 1992 .

[8]  N. Prada,et al.  Novel integrase inhibitors for HIV , 2010, Expert opinion on investigational drugs.

[9]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[10]  F. Bushman,et al.  Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition , 1997, Journal of virology.

[11]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[12]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[13]  R M Stroud,et al.  Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Cihlar,et al.  Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. , 2010, Antiviral research.

[15]  L. Stuyver,et al.  Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. , 2010, The Journal of antimicrobial chemotherapy.

[16]  R. Graham,et al.  Identification of host proteins associated with HIV-1 preintegration complexes isolated from infected CD4+ cells , 2010, Retrovirology.

[17]  Wei Yang,et al.  Structure of a two‐domain fragment of HIV‐1 integrase: implications for domain organization in the intact protein , 2001, The EMBO journal.

[18]  Yves Pommier,et al.  Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. , 2010, Biochemistry.

[19]  A. Engelman,et al.  The Barrier-to-Autointegration Factor Is a Component of Functional Human Immunodeficiency Virus Type 1 Preintegration Complexes , 2003, Journal of Virology.

[20]  A. Engelman,et al.  The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding , 1994, Journal of virology.

[21]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[22]  B. Clotet,et al.  Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  E. Garvey,et al.  Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. , 2008, Antiviral research.

[24]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[25]  D. Kuritzkes,et al.  Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness , 2010, Journal of acquired immune deficiency syndromes.

[26]  F. Bushman.  Host proteins in retroviral cDNA integration. , 1999, Advances in virus research.

[27]  D. Hazuda,et al.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[28]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[29]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[30]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[31]  F. Bushman,et al.  Repair of Gaps in Retroviral DNA Integration Intermediates , 2000, Journal of Virology.

[32]  S. Burgess,et al.  Integration target site selection for retroviruses and transposable elements , 2004, Cellular and Molecular Life Sciences CMLS.

[33]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[34]  Tommy F. Liu,et al.  Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors , 2008, Retrovirology.

[35]  J. Coffin,et al.  Relationship between retroviral DNA-integration-site selection and host cell transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Garvey,et al.  S/GSK1349572 is a Potent Next Generation HIV Integrase Inhibitor , 2009 .

[37]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[38]  L. Stuyver,et al.  The HIV-1 Integrase Mutations Y143C/R Are an Alternative Pathway for Resistance to Raltegravir and Impact the Enzyme Functions , 2010, PloS one.

[39]  Y. Pommier,et al.  Integrase inhibitors to treat HIV/Aids , 2005, Nature Reviews Drug Discovery.

[40]  D. Pillay,et al.  The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy , 2009, AIDS.

[41]  W. Powderly.  Integrase inhibitors in the treatment of HIV-1 infection. , 2010, The Journal of antimicrobial chemotherapy.

[42]  Luba Tchertanov,et al.  Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In Vivo , 2009, Antimicrobial Agents and Chemotherapy.

[43]  M. Bukrinsky,et al.  Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[45]  Yves Pommier,et al.  HIV-1 IN inhibitors: 2010 update and perspectives. , 2009, Current topics in medicinal chemistry.

[46]  Christos J. Petropoulos,et al.  Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways , 2009, Journal of Virology.

[47]  Luba Tchertanov,et al.  The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation , 2008, Nucleic acids research.

[48]  A. Wensing,et al.  Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. , 2010, Antiviral research.

[49]  Deenan Pillay,et al.  Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase , 2008, Journal of Virology.

[50]  V. Calvez,et al.  Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. , 2009, The Journal of antimicrobial chemotherapy.

[51]  Luba Tchertanov,et al.  Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[52]  D. Cooper,et al.  Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.

[53]  E. Clercq.  A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate , 2009 .

[54]  M. de Béthune.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.

[55]  S. Broder,et al.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. , 2010, Antiviral research.

[56]  C. Charpentier,et al.  Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy * , 2008, HIV medicine.

[57]  Dominique Schols,et al.  Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. , 2010, Virology.

[58]  F. Baldanti,et al.  Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens , 2010, Journal of medical virology.

[59]  M. Matsuoka,et al.  Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) , 2007, Journal of Virology.

[60]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[61]  E. Garvey,et al.  Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. , 2009, Antiviral research.

[62]  F. Baldanti,et al.  Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. , 2010, The Journal of antimicrobial chemotherapy.

[63]  Milton C Weinstein,et al.  The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.

[64]  J. Gatell,et al.  Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study , 2010, AIDS.

[65]  C. Crumpacker,et al.  Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.

[66]  C. Woodward,et al.  Integrase Interacts with Nucleoporin NUP153 To Mediate the Nuclear Import of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.

[67]  John M. Coffin,et al.  Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection , 2010, PloS one.

[68]  Robert Craigie,et al.  HIV Integrase, a Brief Overview from Chemistry to Therapeutics* , 2001, The Journal of Biological Chemistry.